The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.